XML 21 R11.htm IDEA: XBRL DOCUMENT

Revenue Recognition	6 Months Ended
Revenue Recognition	Jun. 30, 2019
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition During the three and six months ended June 30, 2019, the Company recognized total revenue under collaborative research and development and other agreements of $62,000 and $2.8 million, respectively, from AstraZeneca and $74,000 and $191,000, respectively, from various other contracts. The Company defers revenue when a contract is entered into with a collaborator and cash payments are received prior to satisfaction of the related performance obligation. Of the total revenue recognized during the three and six months ended June 30, 2019, $36,000 and $215,000, respectively, was in deferred revenue as of December 31, 2018. Of the total revenue recognized during the three and six months ended June 30, 2018, $354,000 and $1.0 million, respectively, was in deferred revenue as of December 31, 2017. Performance obligations are generally satisfied within 12 months of the initial contract date.